A Study of LUCAR-20SP in Subjects With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

This study is testing a new CAR-T cell therapy called LUCAR-20SP for patients with B-cell non-Hodgkin lymphoma that has returned or stopped responding to previous treatments. CAR-T therapy involves taking a patient's own immune cells, engineering them in a lab to recognize and attack cancer cells, and infusing them back into the patient. **You may be eligible if...** - You are 18 years or older - You have been diagnosed with large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, or indolent lymphoma that has transformed — all confirmed by biopsy - Your cancer cells are CD20-positive (a protein on the surface of the cancer cells that the therapy targets) - Your cancer has returned or stopped responding to previous treatment - You have at least one measurable tumor on imaging - Your general health is good (ECOG 0–1) and your life expectancy is at least 3 months **You may NOT be eligible if...** - You have recently received other cancer treatments without an adequate washout period - You have previously received CAR-T or other gene/cell therapy (with some exceptions) - You have active uncontrolled infection or poor organ function Talk to your doctor to see if this trial is right for you.